ATE454137T1 - Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab - Google Patents

Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab

Info

Publication number
ATE454137T1
ATE454137T1 AT02759206T AT02759206T ATE454137T1 AT E454137 T1 ATE454137 T1 AT E454137T1 AT 02759206 T AT02759206 T AT 02759206T AT 02759206 T AT02759206 T AT 02759206T AT E454137 T1 ATE454137 T1 AT E454137T1
Authority
AT
Austria
Prior art keywords
igg antibody
pharmaceutical formulation
lyophilized pharmaceutical
stable
stable lyophilized
Prior art date
Application number
AT02759206T
Other languages
English (en)
Inventor
Elizabet Kaisheva
Aleni Flores-Nate
Supriya Gupta
Original Assignee
Facet Biotech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Facet Biotech Corp filed Critical Facet Biotech Corp
Application granted granted Critical
Publication of ATE454137T1 publication Critical patent/ATE454137T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02759206T 2001-07-25 2002-07-25 Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab ATE454137T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30787801P 2001-07-25 2001-07-25
PCT/US2002/024078 WO2003009817A2 (en) 2001-07-25 2002-07-25 Stable lyophilized pharmaceutical formulation of igg antibodies

Publications (1)

Publication Number Publication Date
ATE454137T1 true ATE454137T1 (de) 2010-01-15

Family

ID=23191544

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02759206T ATE454137T1 (de) 2001-07-25 2002-07-25 Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab

Country Status (10)

Country Link
US (3) US20030113316A1 (de)
EP (1) EP1409018B1 (de)
JP (1) JP4317010B2 (de)
AT (1) ATE454137T1 (de)
AU (1) AU2002324556A1 (de)
CA (1) CA2454587C (de)
DE (1) DE60235013D1 (de)
ES (1) ES2338218T3 (de)
MX (1) MXPA04000747A (de)
WO (1) WO2003009817A2 (de)

Families Citing this family (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
AU2003251592A1 (en) * 2002-06-21 2004-01-06 Biogen Idec Inc. Buffered formulations for concentrating antibodies and methods of use thereof
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
AU2003293543A1 (en) * 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
CN103040732B (zh) 2003-02-10 2015-04-01 伊兰药品公司 免疫球蛋白制剂及其制备方法
AU2012200957B2 (en) * 2003-04-04 2014-10-23 Genentech, Inc. High concentration antibody and protein formulations
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
PT1610820E (pt) * 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
WO2006014965A2 (en) * 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process
ES2395035T3 (es) * 2004-08-17 2013-02-07 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de la IL-1
US7655758B2 (en) 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
US7572893B2 (en) * 2004-08-17 2009-08-11 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
WO2006081171A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP1865986B1 (de) * 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4-antikörperzusammensetzungen
CA3142945A1 (en) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Histidine-buffered formulations of vegf antagonist
AU2006247039B2 (en) * 2005-05-19 2011-03-03 Amgen Inc. Compositions and methods for increasing the stability of antibodies
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
JP5405122B2 (ja) * 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
WO2007095337A2 (en) * 2006-02-15 2007-08-23 Imclone Systems Incorporated Antibody formulation
WO2007112047A2 (en) * 2006-03-24 2007-10-04 Enzon Pharmaceuticals, Inc. Formulations containing immunotoxins targeted to the mesothelin tumor cell antigen
CA2647111A1 (en) * 2006-03-28 2007-10-04 F. Hoffmann-La Roche Ag Anti-igf-1r human monoclonal antibody formulation
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US20080038258A1 (en) * 2006-07-21 2008-02-14 Amgen Inc. Polypeptides with Reduced Susceptibility to Oxidation and Methods of Making
JPWO2008020584A1 (ja) * 2006-08-14 2010-01-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定な凍結乾燥製剤
CA2665567C (en) * 2006-10-06 2012-07-03 Amgen Inc. Stable formulations
US7705132B2 (en) * 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
BRPI0720125A2 (pt) * 2006-12-06 2014-01-28 Wyeth Corp Método para armazenar uma formulação líquida; método para a preparação de uma formulação líquida; composição; e método para inibir a agregação induzida por manitol de uma proteína em uma formulação líquida.
CN101553504A (zh) * 2006-12-11 2009-10-07 豪夫迈·罗氏有限公司 Aβ抗体胃肠外制剂
JP5419709B2 (ja) * 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
ES2610474T3 (es) 2007-01-11 2017-04-27 Michael Bacher Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia
PE20130588A1 (es) * 2007-02-02 2013-05-21 Amgen Inc Hepcidina, antagonistas de la hepcidina y metodos de uso
US20080200656A1 (en) * 2007-02-16 2008-08-21 Wyeth Use Of Sucrose To Suppress Mannitol-Induced Protein Aggregation
AU2008216090A1 (en) * 2007-02-16 2008-08-21 Wyeth Protein formulations containing sorbitol
CA2681743A1 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
KR101540823B1 (ko) * 2007-03-30 2015-07-30 메디뮨 엘엘씨 항체 제제
MX2009010675A (es) * 2007-04-04 2009-10-23 Theratechnologies Inc Formulaciones farmaceuticas de moleculas de la hormona liberadora de la hormona delcrecimiento humana.
CN101678078B (zh) * 2007-04-13 2014-12-10 阿布拉西斯生物科学公司 Sparc及其使用方法
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
EP2170283B1 (de) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Bildung eines stabilen submikron-peptids oder von proteinteilchen durch dünnfilm-gefrieren
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
WO2009037190A2 (en) * 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2803675A3 (de) 2008-01-25 2014-12-24 Amgen, Inc Ferroportin-Antikörper und Anwendungsverfahren
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
WO2010027766A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CA2737045C (en) * 2008-11-20 2017-11-14 Bruce Kabakoff Therapeutic protein formulations
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
EP2403873A1 (de) 2009-03-05 2012-01-11 Ablynx N.V. Neue antigenbindende dimerkomplexe, verfahren zur herstellung/vermeidung und anwendungen davon
US9265834B2 (en) 2009-03-05 2016-02-23 Ablynx N.V. Stable formulations of polypeptides and uses thereof
PE20120359A1 (es) * 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
JP2012521197A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド 担体免疫グロブリンおよびその使用
ES2514319T3 (es) * 2009-05-04 2014-10-28 Abbvie Research B.V. Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada
US20100278822A1 (en) * 2009-05-04 2010-11-04 Abbott Biotechnology, Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
WO2010148321A1 (en) * 2009-06-18 2010-12-23 Wyeth Llc Slow dissolution method for reconstitution of lyophilized material
WO2011017070A1 (en) * 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
AU2010286427A1 (en) 2009-08-31 2012-03-08 Abbott Biotherapeutics Corp. Use of an immunoregulatory NK cell population for monitoring the efficacy of anti-IL-2R antibodies in multiple sclerosis patients
EP2473528B1 (de) 2009-09-03 2014-12-03 Ablynx N.V. Stabile formulierungen aus polypeptiden und verwendungen davon
EP2470901A1 (de) 2009-10-30 2012-07-04 Abbott Biotherapeutics Corp. Verwendung von immunregulatorischen nk-zellpopulationen zur vorhersage der wirksamkeit von anti-il-2r-antikörpern bei patienten mit multipler sklerose
PL3721904T3 (pl) * 2009-11-20 2022-01-31 Biocon Limited Formulacje przeciwciała t1h
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
CA2781666C (en) 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
KR20130031247A (ko) * 2010-03-17 2013-03-28 애보트 리서치 비.브이. 항―신경 성장 인자（ｎｇｆ） 항체 조성물
RU2012153786A (ru) * 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
BR112012033457A2 (pt) * 2010-07-02 2017-04-04 Medimmune Llc formulações de anticorpo.
JOP20190250A1 (ar) * 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
CA2885176C (en) 2010-09-22 2018-10-23 Amgen Inc. Carrier immunoglobulins and uses thereof
AU2011325134B2 (en) 2010-11-05 2014-10-23 Novartis Ag Methods of treating rheumatoid arthritis using IL-17 antagonists
TWI603739B (zh) * 2010-11-11 2017-11-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
CA2825778A1 (en) 2011-01-28 2012-08-02 Sanofi Pharmaceutical compositions comprising human antibodies to pcsk9
CA2829629A1 (en) * 2011-03-10 2012-09-13 Board Of Regents, The University Of Texas System Protein nanoparticle dispersions
WO2012135408A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2773111T3 (es) 2011-09-16 2020-07-09 Regeneron Pharma Inhibidor de la proproteína convertasa subtilisina/kexina 9 (PCSK9) para su uso en la reducción de los niveles de lipoproteína (a)
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
BR112014009866A2 (pt) 2011-10-25 2018-09-04 Onclave Therapeutics Limited formulações de anticorpos e métodos
KR102063028B1 (ko) 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ａｎｇ2 항체를 함유하는 안정화된 제형
KR20160105535A (ko) * 2012-03-07 2016-09-06 카딜라 핼쓰캐어 리미티드 TNF-α 항체의 약제학적 제형
AR092325A1 (es) 2012-05-31 2015-04-15 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
AR093297A1 (es) * 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
US9441051B2 (en) * 2012-11-26 2016-09-13 Albert Ludwigs Universitäfreiburg Matrices comprising modified polysaccharides and modified polysaccharides
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US11576863B2 (en) 2013-03-15 2023-02-14 Takeda Pharmaceutical Company Limited Formulation of an antibody and use thereof
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
RU2714919C2 (ru) 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
EP3041484B1 (de) 2013-09-06 2021-03-03 Academia Sinica Humane inkt-zell-aktivierung mittels glykolipiden mit veränderten glycosylgruppen
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
CN105848645A (zh) * 2013-09-27 2016-08-10 韩美药品株式会社 持续型人生长激素制剂
US20160228371A1 (en) * 2013-10-18 2016-08-11 Abbvie Inc. Stable solid units and methods of making the same
US10428157B2 (en) 2013-11-12 2019-10-01 Sanofi Biotechnology Dosing regimens for use with PCSK9 inhibitors
SI3071237T1 (sl) 2013-11-21 2024-11-29 Genmab A/S Liofilizirana formulacija konjugata protitelo-zdravilo
TW201623331A (zh) * 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
KR20170010003A (ko) 2014-05-27 2017-01-25 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
JP2017518989A (ja) * 2014-05-27 2017-07-13 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗ｃｄ２０糖操作抗体群およびその使用
EP4116329A1 (de) 2014-05-27 2023-01-11 Academia Sinica Anti-her2-glykoantikörper und verwendungen davon
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
WO2015200027A1 (en) * 2014-06-26 2015-12-30 Amgen Inc. Protein formulations
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
US20170231995A1 (en) 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
CN106604744A (zh) * 2014-09-03 2017-04-26 免疫医疗有限公司 稳定的抗IL‑4R‑α抗体配制品
UY36302A (es) 2014-09-15 2016-04-29 Amgen Inc Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
CA2961917A1 (en) 2014-09-22 2016-03-31 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
WO2016115561A1 (en) * 2015-01-18 2016-07-21 Biogen Ma Inc. Formulations and screening of biological therapeutic agents
KR101776879B1 (ko) 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
US11077193B2 (en) 2015-04-21 2021-08-03 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nerve growth factor composition and powder injection
EP3287139B1 (de) 2015-04-21 2021-08-11 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Nervenwachstumsfaktorzusammensetzung und injektionspulver
KR101808234B1 (ko) 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
EA201890519A1 (ru) 2015-08-18 2018-07-31 Ридженерон Фармасьютикалз, Инк. Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
JP6932700B2 (ja) 2015-09-15 2021-09-08 アムジエン・インコーポレーテツド ４価の二重特異性抗原結合タンパク質及び４価の四重特異性抗原結合タンパク質、ならびにそれらの使用
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
WO2017077507A1 (en) 2015-11-06 2017-05-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of bruton's tyrosine kinase
EP3383435A4 (de) * 2015-11-30 2019-07-10 Medimmune, LLC Optimierte verhältnisse von aminosäuren und zuckern als amorphe stabilisierende verbindungen in pharmazeutischen zusammensetzungen mit hohen konzentrationen an proteinbasierten therapeutika
KR20210157427A (ko) 2015-12-03 2021-12-28 리제너론 파마슈티칼스 인코포레이티드 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
EP3394099A4 (de) * 2015-12-22 2019-11-27 Merck Sharp & Dohme Corp. Formulierungen von manipulierten anti-il-10-antikörpern
JP2019505520A (ja) 2016-01-13 2019-02-28 ゲンマブ エー／エス 抗体およびその薬物コンジュゲートの製剤
GB201608323D0 (en) * 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
EP3468610A1 (de) 2016-06-09 2019-04-17 OPKO Biologics Ltd. Langwirkende oxyntomodulinformulierung und verfahren zur herstellung und verabreichung davon
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
EP3534963B1 (de) * 2016-11-02 2024-04-17 Polaris Group Formulierungen von pegylierter arginin-deiminase
AU2017356317A1 (en) 2016-11-14 2019-05-30 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
CA3044082A1 (en) 2017-04-03 2018-10-11 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
EA201900443A1 (ru) * 2017-04-18 2020-03-06 Р-Фарм Оверсиз Инк. Антитело к pd-l1 и его применение
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
UY37753A (es) 2017-06-02 2018-11-30 Amgen Inc Antagonistas de péptido pac1
KR20200093621A (ko) 2017-11-30 2020-08-05 리제너론 파아마슈티컬스, 인크. 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
JP7460608B2 (ja) 2018-05-07 2024-04-02 ジェンマブ エー／エス 抗ｐｄ－１抗体と抗組織因子抗体－薬物コンジュゲートとの組み合わせを用いるがんの治療方法
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
MX2021004356A (es) 2018-10-18 2021-05-31 Merck Sharp & Dohme Llc Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
MA54089A (fr) 2018-10-31 2022-02-09 Merck Sharp & Dohme Anticorps anti-pd-1 humain et procédés d'utilisation associés
JP7503056B6 (ja) 2018-11-07 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤
MX2021007047A (es) * 2018-12-14 2021-10-26 Morphosys Ag Formulaciones de anticuerpos.
JP7542543B2 (ja) 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
JP2022545312A (ja) 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー 関節リウマチの診断及び処置の方法
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
WO2020264384A1 (en) 2019-06-28 2020-12-30 Amgen Inc. Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
CN111110638B (zh) * 2020-01-10 2022-10-14 广州市丹蓝生物科技有限公司 一种偶联有蛋白的微球冻干制剂及其制备方法、保存方式
CA3168170A1 (en) * 2020-03-09 2021-09-16 Pamela Ann Cacavas Method for removing interfering components of a liquid sample prior to dispensing same on a chemical reagent test slide
AU2021235877A1 (en) 2020-03-09 2022-09-22 Idexx Laboratories, Inc. Matrix and associated sample or mixing cup used for removing components of a liquid sample
EP4117625A1 (de) 2020-03-12 2023-01-18 Baxter International Inc. Daptomycin-formulierungen mit einer kombination aus sorbitol und mannitol
JP2024516293A (ja) * 2021-05-07 2024-04-12 ドクター レディズ ラボラトリーズ リミテッド 抗体製剤の安定性を向上させる方法
EP4359438A1 (de) * 2021-06-21 2024-05-01 Bristol-Myers Squibb Company Verwendung von saccharose, mannitol und glycin zur reduzierung der rekonstitutionszeit von hochkonzentrierten lyophilisierten biologischen wirkstoffprodukten
EP4673177A1 (de) * 2023-03-02 2026-01-07 Novetide Ltd. Verfahren zur herstellung von glp-1-peptiden mit kontrollierter teilchengrösse
CN117825688B (zh) * 2024-01-19 2024-05-31 武汉鹰达生物科技有限公司 一种动物IgG抗体冻干粉制剂及其制备工艺

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434680B (sv) * 1983-01-21 1984-08-06 Karl Arne Lundblad Anvendning av en saltlosning av monoklonala antikroppar med relativt hog salthalt vid blodgruppsbestemning
US5091178A (en) * 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4808705A (en) * 1986-12-19 1989-02-28 Cetus Corporation Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
JPH03504605A (ja) * 1988-05-27 1991-10-09 セントカー・インコーポレーテツド 抗体産生物の凍結乾燥した配合物
US5824658A (en) * 1990-09-18 1998-10-20 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
JPH0565233A (ja) * 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US5268368A (en) * 1991-05-17 1993-12-07 Erbamont, Inc. Cyclophosphamide--amino acid lyophilizates
US5792753A (en) * 1991-07-03 1998-08-11 Hyal Pharmaceutical Corporation Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs
US5334380A (en) * 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
SE9302135D0 (sv) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
EP0733371B1 (de) * 1995-03-21 2002-06-19 Baxter Aktiengesellschaft Mittel zur subkutanen Verabreichung von Protein C
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ATE230277T1 (de) * 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations

Also Published As

Publication number Publication date
CA2454587C (en) 2012-11-13
WO2003009817A9 (en) 2004-05-06
US20030113316A1 (en) 2003-06-19
EP1409018A2 (de) 2004-04-21
EP1409018B1 (de) 2010-01-06
DE60235013D1 (de) 2010-02-25
EP1409018A4 (de) 2007-03-28
MXPA04000747A (es) 2004-07-08
AU2002324556A1 (en) 2003-02-17
WO2003009817A2 (en) 2003-02-06
US20060029599A1 (en) 2006-02-09
US7592004B2 (en) 2009-09-22
CA2454587A1 (en) 2003-02-06
WO2003009817A3 (en) 2003-11-27
WO2003009817B1 (en) 2003-12-18
US20100055097A1 (en) 2010-03-04
JP2004538287A (ja) 2004-12-24
JP4317010B2 (ja) 2009-08-19
ES2338218T3 (es) 2010-05-05
US8298530B2 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
DE60235013D1 (de) Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
ES2614815T3 (es) Composiciones inmunogénicas estables de antígenos de Staphylococcus aureus
MX2009012964A (es) Formulacion de peptido estable a alta temperatura.
AR074517A2 (es) Formulacion de proteina liofilizada estable y formulacion reconstituida isotonica estable adecuada para administracion subcutanea
LU93314I2 (de)
RU2007119724A (ru) Композиции, содержащие эктинэсайдин и дисахарид
CA2272245A1 (en) Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies
AR029139A1 (es) Interleuquina 2 estabilizada
EA202193240A1 (ru) Стабилизированные составы, содержащие анти-angptl3 антитела
JP6196975B2 (ja) ポリペプチドの安定化
SI1687019T1 (en) Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Hassett et al. Glassy‐state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid A adjuvants
KR950703987A (ko) G-csf의 안정한 동결건조된 약제학적 제제(stable lyophilized pharma ceutical preparations g-csf)
EP0634937A1 (de) Impfstoffe die nicht ionische tensid vesikeln enthalften.
EA199800938A1 (ru) Композиции, содержащие антигрибковый агент и ацетатный буфер
US7365165B2 (en) IL-1 antagonist formulations
PE20260294A1 (es) Compuestos y formulaciones adyuvantes utiles en vacunas neumococicas
RU2009128327A (ru) Лиофилизированная инъецируемая фармацевтическая композиция полусинтетических алкалоидов vinca и углевода, стабильная при комнатной температуре
Lofthouse et al. The application of biodegradable collagen minipellets as vaccine delivery vehicles in mice and sheep
JP2011516461A (ja) 液体配合物及び凍結乾燥した配合物
CY1113904T1 (el) Σταθερο φαρμακευτικο σκευασμα σε υγρη μορφη αντισωματων igg
AR127813A1 (es) FORMULACIONES FARMACEUTICAS QUE COMRENDEN Fab-PEG
HK1230484A1 (en) Pharmaceutical compositions containing clostridium difficile toxoids a and b
HK1147285A (en) Pharmaceutical compositions containing clostridium difficile toxoids a and b
AR004223A1 (es) Composiciones para inhibir la agregacion de plaquetas y el uso de las mismas en la manufactura de un medicamento.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties